Clinical trials: Progressive Supranuclear Palsy(PSP)
Progressive Supranuclear Palsy
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on…
- Trial name
- CN002-003 (NCT02460094)
- Testing
- BIIB092
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- Biogen
Progressive Supranuclear Palsy, Multiple System Atrophy
The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism
Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA) and corticobasal syndrome (CBS) are severe neurodegenerative diseases with rapid progression and no effective treatment.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Syndrome
- Trial name
- NADAPT (NCT06162013)
- Testing
- Nicotinamide Riboside
- Where
- 3 sites in Norway
- Volunteers
- 330 people
- Sponsor
- Haukeland University Hospital
Progressive Supranuclear Palsy, Parkinson's Disease
Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
Background: Progressive supranuclear palsy (PSP) is a rare neuro-degenerative disease, counted among atypical parkinsonism (AP).
- Trial name
- DeepTMSPARK (NCT02734485)
- Testing
- active Deep TMS
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS San Raffaele Roma
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
PSP, CBD
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months.
- Conditions
- PSP, CBD, Progressive Supranuclear Palsy, FTD
- Trial name
- NCT05956834
- Testing
- PAMSys, LEGSys
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Progressive Supranuclear Palsy
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
- Trial name
- Tauros (NCT01049399)
- Testing
- tideglusib
- Where
- 24 sites in United States, Germany and 2 more
- Volunteers
- 146 people
- Sponsor
- Noscira SA
Parkinson Disease, Progressive Supranuclear Palsy
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
To perform a prospective cohort study with [(18)F]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features…
- Trial name
- NCT05459753
- Testing
- (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET, Dihydrotetrabenazine (DTBZ) PET
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Progressive Supranuclear Palsy
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy.
- Trial name
- NCT04008355
- Testing
- AZP2006 oral solution
- Where
- 3 sites in France
- Volunteers
- 36 people
- Sponsor
- AlzProtect SAS
Progressive Supranuclear Palsy
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists.
- Trial name
- NCT00382824
- Testing
- Coenzyme Q10
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Lahey Clinic
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Human CNS Tau Kinetics in Tauopathies
The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD MAPT Mutation)
- Trial name
- TANGLES (NCT03545126)
- Testing
- 13C6 Leucine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Progressive Supranuclear Palsy
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT02985879
- Testing
- ABBV-8E12
- Where
- 66 sites in United States, Australia and 6 more
- Volunteers
- 378 people
- Sponsor
- AbbVie